Traws Pharma, Inc.
TRAW
$1.98
-$0.01-0.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 226.00K | 226.00K | 226.00K | 226.00K | 226.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 226.00K | 226.00K | 226.00K | 226.00K | 226.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 226.00K | 226.00K | 226.00K | 226.00K | 226.00K |
| SG&A Expenses | 12.29M | 10.90M | 10.10M | 10.34M | 9.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.14M | 24.32M | 20.87M | 19.60M | 20.52M |
| Operating Income | -24.91M | -24.09M | -20.65M | -19.37M | -20.30M |
| Income Before Tax | -166.52M | -140.79M | -137.05M | -18.16M | -18.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -166.52 | -140.79 | -137.05 | -18.16 | -18.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -166.52M | -140.79M | -137.05M | -18.16M | -18.95M |
| EBIT | -24.91M | -24.09M | -20.65M | -19.37M | -20.30M |
| EBITDA | -24.90M | -24.08M | -20.63M | -19.36M | -20.28M |
| EPS Basic | -109.76 | -141.34 | -138.17 | -21.60 | -22.57 |
| Normalized Basic EPS | -18.79 | -15.83 | -13.84 | -13.50 | -14.11 |
| EPS Diluted | -109.76 | -141.34 | -138.17 | -21.60 | -22.57 |
| Normalized Diluted EPS | -18.79 | -15.83 | -13.84 | -13.50 | -14.11 |
| Average Basic Shares Outstanding | 5.90M | 3.66M | 3.53M | 3.36M | 3.36M |
| Average Diluted Shares Outstanding | 5.90M | 3.66M | 3.53M | 3.36M | 3.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |